Zavicefta, Ceftazidime-Avibactam
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hospital-Acquired Pneumonia
Conditions
Hospital-Acquired Pneumonia
Trial Timeline
May 21, 2021 → May 4, 2023
NCT ID
NCT04774094About Zavicefta, Ceftazidime-Avibactam
Zavicefta, Ceftazidime-Avibactam is a approved stage product being developed by Pfizer for Hospital-Acquired Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT04774094. Target conditions include Hospital-Acquired Pneumonia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04774094 | Approved | Completed |
Competing Products
2 competing products in Hospital-Acquired Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-8427 + Meropenem | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| IMI/REL FDC + PIP/TAZ FDC + Linezolid | Merck | Phase 3 | 77 |